NPJ Breast CancerPub Date : 2024-12-19DOI: 10.1038/s41523-024-00714-7
Kung-Chi Chang, Francesca Silvestri, Michael U J Oliphant, M Angie Martinez-Gakidis, Dennis P Orgill, Judy E Garber, Deborah D Dillon, Joan S Brugge
{"title":"Breast organoid suspension cultures maintain long-term estrogen receptor expression and responsiveness.","authors":"Kung-Chi Chang, Francesca Silvestri, Michael U J Oliphant, M Angie Martinez-Gakidis, Dennis P Orgill, Judy E Garber, Deborah D Dillon, Joan S Brugge","doi":"10.1038/s41523-024-00714-7","DOIUrl":"10.1038/s41523-024-00714-7","url":null,"abstract":"<p><p>Organoid cultures offer a powerful technology to investigate many different aspects of development, physiology, and pathology of diverse tissues. Unlike standard tissue culture of primary breast epithelial cells, breast organoids preserve the epithelial lineages and architecture of the normal tissue. However, existing organoid culture methods are tedious, difficult to scale, and do not robustly retain estrogen receptor (ER) expression and responsiveness in long-term culture. Here, we describe a modified culture method to generate and maintain organoids as suspension cultures in reconstituted basement membrane (™Matrigel). This method improves organoid growth and uniformity compared to the conventional Matrigel dome embedding method, while maintaining the fidelity of the three major epithelial lineages. Using this adopted method, we are able to culture and passage purified hormone sensing (HS) cells that retain ER responsiveness upon estrogen stimulation in long-term culture. This culture system presents a valuable platform to study the events involved in initiation and evolution of ER-positive breast cancer.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"10 1","pages":"107"},"PeriodicalIF":6.5,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11659324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ Breast CancerPub Date : 2024-12-19DOI: 10.1038/s41523-024-00709-4
Zheqi Li, Fangyuan Chen, Li Chen, Jiebin Liu, Danielle Tseng, Fazal Hadi, Soleilmane Omarjee, Kamal Kishore, Joshua Kent, Joanna Kirkpatrick, Clive D'Santos, Mandy Lawson, Jason Gertz, Matthew J Sikora, Donald P McDonnell, Jason S Carroll, Kornelia Polyak, Steffi Oesterreich, Adrian V Lee
{"title":"The EstroGene2.0 database for endocrine therapy response and resistance in breast cancer.","authors":"Zheqi Li, Fangyuan Chen, Li Chen, Jiebin Liu, Danielle Tseng, Fazal Hadi, Soleilmane Omarjee, Kamal Kishore, Joshua Kent, Joanna Kirkpatrick, Clive D'Santos, Mandy Lawson, Jason Gertz, Matthew J Sikora, Donald P McDonnell, Jason S Carroll, Kornelia Polyak, Steffi Oesterreich, Adrian V Lee","doi":"10.1038/s41523-024-00709-4","DOIUrl":"10.1038/s41523-024-00709-4","url":null,"abstract":"<p><p>Endocrine therapies targeting the estrogen receptor (ER/ESR1) are the cornerstone to treat ER-positive breast cancers patients, but resistance often limits their effectiveness. Notable progress has been made although the fragmented way data is reported has reduced their potential impact. Here, we introduce EstroGene2.0, an expanded database of its precursor 1.0 version. EstroGene2.0 focusses on response and resistance to endocrine therapies in breast cancer models. Incorporating multi-omic profiling of 361 experiments from 212 studies across 28 cell lines, a user-friendly browser offers comprehensive data visualization and metadata mining capabilities ( https://estrogeneii.web.app/ ). Taking advantage of the harmonized data collection, our follow-up meta-analysis revealed transcriptomic landscape and substantial diversity in response to different classes of ER modulators. Endocrine-resistant models exhibit a spectrum of transcriptomic alterations including a contra-directional shift in ER and interferon signalings, which is recapitulated clinically. Dissecting multiple ESR1-mutant cell models revealed the different clinical relevance of cell model engineering and identified high-confidence mutant-ER targets, such as NPY1R. These examples demonstrate how EstroGene2.0 helps investigate breast cancer's response to endocrine therapies and explore resistance mechanisms.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"10 1","pages":"106"},"PeriodicalIF":6.5,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11659402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ Breast CancerPub Date : 2024-12-18DOI: 10.1038/s41523-024-00713-8
Linda Cucciniello, Eva Blondeaux, Claudia Bighin, Simona Gasparro, Stefania Russo, Arianna Dri, Palma Pugliese, Andrea Fontana, Enrico Cortesi, Antonella Ferzi, Ferdinando Riccardi, Valentina Sini, Luca Boni, Alessandra Fabi, Filippo Montemurro, Michelino De Laurentiis, Grazia Arpino, Lucia Del Mastro, Lorenzo Gerratana, Fabio Puglisi
{"title":"Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer.","authors":"Linda Cucciniello, Eva Blondeaux, Claudia Bighin, Simona Gasparro, Stefania Russo, Arianna Dri, Palma Pugliese, Andrea Fontana, Enrico Cortesi, Antonella Ferzi, Ferdinando Riccardi, Valentina Sini, Luca Boni, Alessandra Fabi, Filippo Montemurro, Michelino De Laurentiis, Grazia Arpino, Lucia Del Mastro, Lorenzo Gerratana, Fabio Puglisi","doi":"10.1038/s41523-024-00713-8","DOIUrl":"10.1038/s41523-024-00713-8","url":null,"abstract":"<p><p>This study aimed to identify the clinico-pathological variables predictive of radiologic complete response (rCR) to first-line anti-HER2 therapy in patients with HER2-positive metastatic breast cancer. Patients were selected from the database of the GIM14 study and classified according to the best radiologic response obtained to first-line anti-HER2 therapy and upon time-to-treatment-discontinuation (TTD). A total of 545 patients were included in the analysis. Eighty patients experienced a rCR to first-line anti-HER2 therapy with a TTD > 3 months and HER2 Immunohistochemistry score 3+, presence of non-visceral metastases and 1 metastatic site were significantly associated with higher odds of obtaining a CR. Of the 80 patients achieving a rCR, 56 experienced a CR with a TTD > 18 months, with anti-HER2 therapy being the only variable significantly associated with a higher probability of achieving such sustained CR.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"10 1","pages":"105"},"PeriodicalIF":6.5,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ Breast CancerPub Date : 2024-12-06DOI: 10.1038/s41523-024-00704-9
Fatima Cardoso, Kim M Hirshfield, Kimberly A Kraynyak, Konstantinos Tryfonidis, Aditya Bardia
{"title":"Immunotherapy for hormone receptor‒positive HER2-negative breast cancer.","authors":"Fatima Cardoso, Kim M Hirshfield, Kimberly A Kraynyak, Konstantinos Tryfonidis, Aditya Bardia","doi":"10.1038/s41523-024-00704-9","DOIUrl":"10.1038/s41523-024-00704-9","url":null,"abstract":"<p><p>Additional therapies are needed to improve outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Research on the potential role of immunotherapy, particularly programmed cell death protein 1/programmed cell death ligand 1 inhibitors, is rapidly expanding in both the early and metastatic settings with some preliminary evidence suggesting benefit when used as part of combination therapy. Several ongoing phase 3 studies should help define their future role in treating these patients.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"10 1","pages":"104"},"PeriodicalIF":6.5,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11624285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ Breast CancerPub Date : 2024-11-29DOI: 10.1038/s41523-024-00706-7
Thibault Thomas-Bonafos, Jean Yves Pierga, François-Clément Bidard, Luc Cabel, Nicolas Kiavue
{"title":"Circulating tumor cells in breast cancer: clinical validity and utility.","authors":"Thibault Thomas-Bonafos, Jean Yves Pierga, François-Clément Bidard, Luc Cabel, Nicolas Kiavue","doi":"10.1038/s41523-024-00706-7","DOIUrl":"10.1038/s41523-024-00706-7","url":null,"abstract":"<p><p>Circulating tumor cells (CTCs) have been extensively studied in breast cancer (BC), with large studies establishing CTCs as a robust prognostic biomarker in early and metastatic breast cancer (MBC). Several phase II and phase III trials have investigated the clinical utility of CTCs in BC. Here, we outline the current landscape for the use of CTCs in the clinic at different stages of BC, focusing first on early BC, then on MBC, with a particular focus on interventional clinical trials based on CTCs.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"10 1","pages":"103"},"PeriodicalIF":6.5,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11606964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ Breast CancerPub Date : 2024-11-26DOI: 10.1038/s41523-024-00710-x
Sonia Pernas, Esther Sanfeliu, Guillermo Villacampa, Javier Salvador, Antonia Perelló, Xavier González, Begoña Jiménez, María Merino, Patricia Palacios, Tomás Pascual, Emilio Alba, Lorea Villanueva, Samyukta Chillara, Juan Manuel Ferrero-Cafiero, Patricia Galvan, Aleix Prat, Eva Ciruelos
{"title":"Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy.","authors":"Sonia Pernas, Esther Sanfeliu, Guillermo Villacampa, Javier Salvador, Antonia Perelló, Xavier González, Begoña Jiménez, María Merino, Patricia Palacios, Tomás Pascual, Emilio Alba, Lorea Villanueva, Samyukta Chillara, Juan Manuel Ferrero-Cafiero, Patricia Galvan, Aleix Prat, Eva Ciruelos","doi":"10.1038/s41523-024-00710-x","DOIUrl":"10.1038/s41523-024-00710-x","url":null,"abstract":"<p><p>With the incorporation of cyclin-dependent kinase inhibitors in early breast cancer (BC), a better identification of biomarkers is needed. The PROMETEO II trial aimed to evaluate the antitumor activity of palbociclib plus letrozole and to identify response biomarkers in patients with operable HR+/HER2- BC and residual disease after neoadjuvant chemotherapy (NAC). The primary endpoint was the rate of complete cell cycle arrest (CCCA), centrally determined by Ki67 ≤ 2.7% at surgery. A comprehensive translational analysis was conducted. At surgery, the CCCA rate was 59.1%, with a 44.2% decrease in Ki67 from the end of NAC. Changes in intrinsic subtypes occurred in 48% of patients, with proliferation genes suppressed, and immune genes more upregulated in tumors with CCCA. Overall, 14% of tumors were classified as PD-L1<sup>+</sup> after palbociclib. Nine patients experienced grade 3 adverse events (AEs). Palbociclib showed an anti-proliferative effect, with increased immune infiltration in residual tumors with CCCA.Trial registration: Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy (PROMETEO II) ClinicalTrial.gov number NCT04130152. Study registration; October 17, 2019.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"10 1","pages":"101"},"PeriodicalIF":6.5,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ Breast CancerPub Date : 2024-11-26DOI: 10.1038/s41523-024-00712-9
Su-Jin Shin, Inho Park, Heounjeong Go, Jiwon Ko, Yangkyu Lee, Jee Hung Kim, Sung Gwe Ahn, Joon Jeong, Soong June Bae, Yoon Jin Cha
{"title":"Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative.","authors":"Su-Jin Shin, Inho Park, Heounjeong Go, Jiwon Ko, Yangkyu Lee, Jee Hung Kim, Sung Gwe Ahn, Joon Jeong, Soong June Bae, Yoon Jin Cha","doi":"10.1038/s41523-024-00712-9","DOIUrl":"10.1038/s41523-024-00712-9","url":null,"abstract":"<p><p>This study explores differences in immune cell (IC) composition and spatial distribution between triple-negative breast cancer (TNBC) and hormone receptor-positive, HER2-negative breast cancer (HR + HER2-BC) in high-TIL (≥60%) cases, focusing on PD-L1 status. Using multiplex immunofluorescence on resected tumor tissues from 18 TNBC and 14 HR + HER2-BC cases, we analyzed IC types (CD20, CD8, CD4, FOXP3) and their spatial interactions. TNBC showed a unique IC composition characterized by a higher proportion of CD8 + IC (stroma: 27% vs 17%, p < 0.001; tumor: 54% vs 31%, p < 0.001) and CD4 + FOXP3 + IC (stroma: 3.9% vs 3.0%, p = 0.036), compared to HR + HER2-BC. Notably, PD-L1 positive TNBC cases demonstrated denser infiltration CD4 + FOXP3 + IC in the stromal region compared to HR + HER2-BC (146.4 ± 67.1/mm<sup>2</sup> vs 114.3 ± 146.9/mm<sup>2</sup>, p = 0.036), along with pronounced IC clustering near TC. Both tumor subtypes displayed varied IC compositions based on PD-L1 status. In conclusion, IC composition and spatial distribution in high-TIL TNBC and HR + HER2-BC significantly differ, influenced by PD-L1 status.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"10 1","pages":"102"},"PeriodicalIF":6.5,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ Breast CancerPub Date : 2024-11-21DOI: 10.1038/s41523-024-00711-w
Vaseem M Khatri, Mariella A Mestres-Villanueva, Sreenija Yarlagadda, Ajay Doniparthi, David B Smith, Justyn Y Nakashima, John M Bryant, Dekuang Zhao, Rituraj Upadhyay, Matthew N Mills, Daniel E Oliver, Hsiang-Hsuan Michael Yu, Joshua D Palmer, Nicole O Williams, Reshma L Mahtani, Manmeet S Ahluwalia, Hatem H Soliman, Hyo S Han, Aixa E Soyano, Youngchul Kim, Rupesh Kotecha, Sasha J Beyer, Kamran A Ahmed
{"title":"Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases.","authors":"Vaseem M Khatri, Mariella A Mestres-Villanueva, Sreenija Yarlagadda, Ajay Doniparthi, David B Smith, Justyn Y Nakashima, John M Bryant, Dekuang Zhao, Rituraj Upadhyay, Matthew N Mills, Daniel E Oliver, Hsiang-Hsuan Michael Yu, Joshua D Palmer, Nicole O Williams, Reshma L Mahtani, Manmeet S Ahluwalia, Hatem H Soliman, Hyo S Han, Aixa E Soyano, Youngchul Kim, Rupesh Kotecha, Sasha J Beyer, Kamran A Ahmed","doi":"10.1038/s41523-024-00711-w","DOIUrl":"10.1038/s41523-024-00711-w","url":null,"abstract":"<p><p>Trastuzumab-deruxtecan (T-DXd) has demonstrated intracranial efficacy; however, safety and efficacy data remains limited with stereotactic radiosurgery (SRS). A multi-institutional review was performed with HER2+ or HER2-low metastatic breast cancer treated with T-DXd and SRS for active brain metastases. We identified 215 lesions treated over 48 SRS courses in 34 patients. Median follow up from T-DXd initiation was 13.9 months. The cumulative incidence of symptomatic radiation necrosis at 24 months per lesion was 2.1% and per patient 11%. The 12-month LC was 97%. HER2-low was associated with worse distant intracranial control (DIC) (adjusted HR 2.5, 95% CI 1.1-5.6, p = 0.03) and worse systemic progression free survival (PFS) (HR 4.1, 95% CI 1.6-10.7, p = 0.004). Concurrent SRS and T-DXd has excellent local control, without an increased risk of radiation necrosis. HER2-low disease is associated with worse systemic PFS and DIC with T-DXd compared to HER2+.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"10 1","pages":"100"},"PeriodicalIF":6.5,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11582691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ Breast CancerPub Date : 2024-11-15DOI: 10.1038/s41523-024-00707-6
Lauren D Otto-Dobos, Lindsay D Strehle, Brett R Loman, Melina M Seng, Sagar D Sardesai, Nicole O Williams, Margaret E Gatti-Mays, Daniel G Stover, Preeti K Sudheendra, Robert Wesolowski, Rebecca R Andridge, Michael T Bailey, Leah M Pyter
{"title":"Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer.","authors":"Lauren D Otto-Dobos, Lindsay D Strehle, Brett R Loman, Melina M Seng, Sagar D Sardesai, Nicole O Williams, Margaret E Gatti-Mays, Daniel G Stover, Preeti K Sudheendra, Robert Wesolowski, Rebecca R Andridge, Michael T Bailey, Leah M Pyter","doi":"10.1038/s41523-024-00707-6","DOIUrl":"10.1038/s41523-024-00707-6","url":null,"abstract":"<p><p>Chemotherapy frequently causes debilitating gastrointestinal symptoms, which are inadequately managed by current treatments. Recent research indicates the gut microbiome plays a role in the pathogenesis of these symptoms. The current study aimed to identify pre-chemotherapy microbiome markers that predict gastrointestinal symptom severity after breast cancer chemotherapy. Fecal samples, blood, and gastrointestinal symptom scores were collected from 59 breast cancer patients before, during, and after chemotherapy. Lower pre-chemotherapy microbiome alpha diversity and abundance of specific microbes (e.g., Faecalibacterium) predicted greater chemotherapy-induced gastrointestinal symptoms. Notably, tumor and diet characteristics were associated with lower pre-chemotherapy alpha diversity. Lower baseline alpha diversity also predicted higher chemotherapy-induced microbiome disruption, which was positively associated with diarrhea symptoms. The results indicate certain cancer patients have lower microbiome diversity before chemotherapy, which is predictive of greater chemotherapy-induced gastrointestinal symptoms and a less resilient microbiome. These patients may be strong candidates for pre-chemotherapy microbiome-directed preventative interventions (e.g., diet change).</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"10 1","pages":"99"},"PeriodicalIF":6.5,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ Breast CancerPub Date : 2024-11-14DOI: 10.1038/s41523-024-00696-6
Michelle Weitz, J R Pfeiffer, Snehal Patel, Matthew Biancalana, Arda Pekis, Vignesh Kannan, Evandros Kaklamanos, Amanda Parker, Jesse E Bucksot, José Rubio Romera, Ryan Alvin, Yuhan Zhang, Andrew T Stefka, Dorys Lopez-Ramos, Joseph R Peterson, Anuja K Antony, Kathryn W Zamora, Stefanie Woodard
{"title":"Performance of an AI-powered visualization software platform for precision surgery in breast cancer patients.","authors":"Michelle Weitz, J R Pfeiffer, Snehal Patel, Matthew Biancalana, Arda Pekis, Vignesh Kannan, Evandros Kaklamanos, Amanda Parker, Jesse E Bucksot, José Rubio Romera, Ryan Alvin, Yuhan Zhang, Andrew T Stefka, Dorys Lopez-Ramos, Joseph R Peterson, Anuja K Antony, Kathryn W Zamora, Stefanie Woodard","doi":"10.1038/s41523-024-00696-6","DOIUrl":"10.1038/s41523-024-00696-6","url":null,"abstract":"<p><p>Surgery remains the primary treatment modality in the management of early-stage invasive breast cancer. Artificial intelligence (AI)-powered visualization platforms offer the compelling potential to aid surgeons in evaluating the tumor's location and morphology within the breast and accordingly optimize their surgical approach. We sought to validate an AI platform that employs dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to render three-dimensional (3D) representations of the tumor and 5 additional chest tissues, offering clear visualizations as well as functionalities for quantifying tumor morphology, tumor-to-landmark structure distances, excision volumes, and approximate surgical margins. This retrospective study assessed the visualization platform's performance on 100 cases with ground-truth labels vetted by 2 breast-specialized radiologists. We assessed features including automatic AI-generated clinical metrics (e.g., tumor dimensions) as well as visualization tools including convex hulls at desired margins around the tumor to help visualize lumpectomy volume. The statistical performance of the platform's automated features was robust and within the range of inter-radiologist variability. These detailed 3D tumor and surrounding multi-tissue depictions offer both qualitative and quantitative comprehension of cancer topology and may aid in formulating an optimal surgical approach for breast cancer treatment. We further establish the framework for broader data integration into the platform to enhance precision cancer care.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"10 1","pages":"98"},"PeriodicalIF":6.5,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11564706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
